日前，上海长森药业有限公司（下称“长森药业”）宣布完成数亿元人民币B+轮融资，本轮融资由启明创投领投，厦门建发、金易赋新、科投股份旗下辰耀资本、楚昌资本等机构跟投。本轮融资主要用于推进核心管线的关键临床研究及全球化布局。

长森药业由全球知名化学药物研发专家王喆博士于2012年创立。公司致力于自主研发全球首创（First-in-class，FIC）、同靶点最好（Best-in-class，BIC，新一代）、拥有全球知识产权的创新药产品，满足临床未被满足的需求。长森药业现有发明专利近100项，是上海市“专精特新”企业，承担多项科技部、上海市重大专项课题。

长森药业创始人王喆博士是国家特聘专家，京津冀领军人才、上海创业领军人才等。王喆博士师从哈佛大学诺贝尔化学奖得主E.J.Corey教授，深耕药物开发研究30余年，拥有从项目立项到药物上市的完整产业链经验，在抗感染、抗病毒及抗癌新药研发领域成就卓著。

王喆博士所创立的长森药业专注于免疫抗病毒、自身免疫疾病、肿瘤免疫治疗等领域的创新药开发与产业化，目前已有多项适应症进入临床II期及III期工作，其核心产品临床数据表现达到国际领先水平（BIC，FIC），尤其是全球首创的双功能双靶点乙肝完全治愈新药LW231，以及更安全有效的新一代自免疫疾病药物LW402，将极大地满足相关领域的临床需求，有望成为相关领域的重大突破性成果。

作为全球首创（FIC）的双功能双靶点免疫抗病毒治疗乙肝新药，LW231有望实现停药后不反弹，或将突破乙肝无药可完全治愈的世界难题。根据《慢性乙型肝炎防治指南（2022年版）》，乙肝完全治愈的标志性指标为肝细胞HBV DNA(包括核内的cccDNA）的清除，并且停药后不反弹。LW231的临床前研究数据显示目前全球仅LW231达到这一指标。该项目获评2024年全国颠覆性技术创新大赛最高奖项——卓越奖，同年获得国家科技部重点研发计划颠覆性专项支持。

LW402是长森药业自主研发的新一代自免疫疾病领军创新药物，在多个适应症的临床研究中均展现出优异的安全性与疗效，大幅优于同类药物已公布数据。以中重度类风湿关节炎和特异性皮炎的II期临床数据显示为例,LW402不仅起效迅速，疗效好，且毒副作用小，患者疾病的改善/治疗指标效果显著高于其他JAK抑制剂，安慰剂组与各治疗组间的总不良事件发生率无统计学差异，体现了长期安全用药的特征，具有突破性优势，拥有成为全球同类产品最好（BIC）的潜质。

王喆博士表示：“感谢各位投资人的信任与支持。在当前市场环境下，本轮融资的顺利完成，充分体现了投资人对我们管线临床竞争力和市场潜力的高度认可。此次融资为公司注入了充足资金，也标志着长森药业即将从临床验证阶段迈入快速商业化的准备阶段。我们将加快推进完成自免疫药物的关键临床研究及乙肝药物等临床研究，早日实现产品上市。”

启明创投合伙人、医疗创新领域共同负责人陈侃博士表示：“长森药业在免疫抗病毒和自免疫疾病方面取得的突破令人振奋，其技术具有全球领先优势，临床价值高，市场潜力巨大。启明创投会不断支持公司的创新发展与国际化布局，共同推进核心管线的商业化进程。”

长森药业成立于2012年，是由全球知名化学药物研发专家领衔的创新药研发公司。公司致力于自主研发国际领先的，拥有全球知识产权的创新药产品，立足解决临床未被满足的需求。公司聚焦抗免疫抗病毒、免疫抗肿瘤、自身免疫疾病等领域的创新药开发与产业化，已开展多个自主研发的小分子创新药项目（FIC），多个产品进入临床试验阶段。核心产品临床评估指标达到国际领先水平，有望获得相关领域的重大突破性成果。

启明创投成立于2006年。目前，启明创投旗下管理11只美元基金，7只人民币基金，已募管理资产总额达到95亿美元。自成立至今，专注于投资科技及消费（Technology and Consumer, T&C）、医疗创新（Healthcare）等行业早期和成长期的优秀企业。截至目前，启明创投已投资超过580家高速成长的创新企业，其中有超过210家分别在美国纽交所、纳斯达克，香港交易所，上交所及深交所等交易所上市，或通过并购等方式退出，有80多家企业成为行业公认的独角兽或超级独角兽企业。

Longwood Biopharmaceuticals Secures Hundreds of Millions in Series B+ Financing to Accelerate Core Pipeline Clinical Research and Global Layout

Recently, Shanghai Longwood Biopharmaceuticals Co., Ltd. (hereinafter referred to as “Longwood Biopharmaceuticals”) announced the completion of its Series B+ financing round, raising hundreds of millions of RMB. Qiming Venture Partners led this round of investment, with participation from institutions including Xiamen C&D, Jinyi Fuxin, Chenyao Capital, and CCIC. The funds raised in this round will be mainly used to advance the core pipelines and the company's global layout.

Founded in 2012 by Dr. Zhe Wang, a world-renowned expert in chemical drug R&D, Longwood Biopharmaceuticals is committed to the independent R&D of innovative drugs that are First-in-class (FIC), Best-in-class (BIC), and hold global intellectual property rights, aiming to meet unmet clinical needs. The company holds nearly 100 invention patents (including more than 30 PCT international patents).

Dr. Zhe Wang, founder of Longwood Biopharmaceuticals, is a National Special Expert, mentored by Professor E.J. Corey, a Nobel laureate in Chemistry from Harvard University. Dr. Wang has over 30 years of experience in drug development. He possesses comprehensive experience covering the entire industrial chain from project initiation to drug commercialization, and has made outstanding achievements in the R&D of new drugs for anti-infection, anti-virus, and anti-cancer treatments.  

Longwood Biopharmaceuticals focuses on the R&D and industrialization of innovative drugs in fields such as immune antiviral, autoimmune diseases, and tumor immunotherapy. Currently, multiple indications of its innovative drugs have entered Phase II and III clinical trials. The clinical data of its core products have reached internationally leading levels (BIC/FIC). In particular, LW231, the World's First bi-functional and dual-target new drug for the complete cure of hepatitis B, and LW402, a next generation JAK1-selective inhibitor with improved safety and efficacy for autoimmune diseases, will greatly meet clinical needs in relevant fields and are expected to become major breakthrough achievements in related fields.

(1) LW231 – The World's First-in-class Drug for the Complete Cure of Hepatitis B

As the World's First bi-functional and dual-target new immune antiviral drug for hepatitis B, LW231 is expected to achieve no rebound after discontinuation. According to the “Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2022 Edition)”, the hallmark indicator of complete cure for hepatitis B is the clearance of HBV DNA (including covalently closed circular DNA, cccDNA) in hepatocytes, with no rebound after discontinuation. Pre-clinical research data shows that LW231 is currently the only drug worldwide that meets this criterion.

(2) LW402 – The Next-Generation Leading Drug for Autoimmune Diseases

LW402 is a next-generation leading innovative drug for autoimmune diseases independently developed by Longwood Biopharmaceuticals. It has shown excellent safety and efficacy in clinical trials across multiple indications, significantly better than the published data of similar drugs. Taking the Phase II clinical data for moderate-to-severe rheumatoid arthritis and atopic dermatitis as examples, LW402 exhibits rapid onset, high efficacy, and low toxicity. The disease improvement/treatment indicators of patients are significantly higher than those of other JAK inhibitors. Meanwhile, there is no statistical difference in the total incidence of adverse events between the placebo group and each treatment group, reflecting its long-term use features. With such breakthrough advantages, LW402 has the potential to become the Best-in-class (BIC) product among similar products globally.

Dr. Zhe Wang stated, "We would like to thank all investors for their trust and support. The successful completion of this round of financing in the current market environment fully demonstrates investors' high recognition of the clinical competitiveness and market potential of our pipelines. This financing has injected sufficient funds into the company and also marks that Longwood Biopharmaceuticals is about to move from the clinical verification stage to the preparation stage for rapid commercialization. We will accelerate the completion of key clinical research on autoimmune drugs and clinical studies on hepatitis B drugs, striving to launch our products as soon as possible."  

Dr. Kan Chen, Partner of Qiming Venture Partners and Co-Head of the Healthcare Sector, said, "The breakthroughs achieved by Longwood Biopharmaceuticals in immune antiviral and autoimmune diseases are inspiring. Its innovative drugs have global leading advantages, high clinical value, and huge market potential. Qiming Venture Partners will continue to support the company's innovative development and international layout, and jointly promote the commercialization process of core pipelines."

Founded in 2012, Longwood Biopharmaceuticals is an innovative drug R&D company led by world-renowned experts in chemical drug R&D. The company is committed to the independent R&D of internationally leading innovative drugs with global intellectual property rights, focusing on addressing unmet clinical needs. It concentrates on the R&D and industrialization of innovative drugs in fields such as immune antiviral, immune anti-tumor, and autoimmune diseases, and has launched multiple independently developed small-molecule innovative drug projects (FIC), with several products entering the clinical trial stage. The clinical evaluation indicators of its core products have reached internationally leading levels, and they are expected to become major breakthrough achievements in relevant fields.

Qiming Venture Partners was founded in 2006. Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companies in the Technology and Healthcare industries at the early and growth stages.

Since our establishment, Qiming Venture Partners has earned extensive recognition from investors worldwide and has become an ideal VC firm for entrepreneurs, due to our exceptional investment performance. Qiming Venture Partners and our partners consistently rank among the leaders in the global venture capital industry across various prestigious lists.